Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Placebo-Controlled, Double-Blind Randomized Phase II Trial of Neoadjuvant Treatment With Single-Agent Bevacizumab or Placebo, Followed by Six Cycles of Docetaxel, Doxorubicin, and Cyclophosphamide (TAC), With or Without Bevacizumab in Patients With Stage II or Stage III Breast Cancer

NCT00203372 is registered in ClinicalTrials.gov with Translational Oncology Research International as lead sponsor.

NCT NCT00203372
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00203372 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Placebo-Controlled, Double-Blind Randomized Phase II Trial of Neoadjuvant Treatment With Single-Agent Bevacizumab or Placebo, Followed by Six Cycles of Docetaxel, Doxorubicin, and Cyclophosphamide (TAC), With or Without Bevacizumab in Patients With Stage II or Stage III Breast Cancer
Lead sponsor
Translational Oncology Research International
Phase
Phase 2
Overall status
Completed
Start date
May 31, 2005
Completion date
Not reported
Enrollment
6 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer